Obsessive-Compulsive Disorder Clinical Trial
Official title:
A Double-Blind, Randomized, Placebo-Controlled Study of Tolcapone for OCD
The primary aim of the present study is to examine the efficacy and safety of tolcapone in adults with moderate to severe OCD.
Based on the mechanism of action and our previous pilot data, the primary aim of the present study is to examine the efficacy and safety of 8-week treatment with tolcapone vs. placebo in adults with moderate to severe OCD, as indicated by a score of at least 21 on the Yale Brown Obsessive Compulsive Scale (YBOCS), a scale of illness severity, at the baseline visit. We hypothesize that tolcapone will significantly improve symptoms of OCD compared to placebo. A secondary aim of the proposed study is to examine the cognitive effects of tolcapone in OCD, by conducting objective neuropsychological tasks pre- and post-pharmacological trial. The rationale for this approach is that: dopamine plays a key role in cognition; cognitive effects of tolcapone are likely to be relevant in explaining symptomatic effects; and cognitive dysfunction constitutes an important treatment target in OCD that is not generally ameliorated by current first-line interventions. We hypothesize that any symptomatic benefit with tolcapone would also be associated with improvement in executive functions including cognitive flexibility. Another secondary aim of the proposed study is to evaluate whether the single nucleotide polymorphism (SNP) Val-158-Met polymorphism significantly relates to changes in symptoms and cognition observed with tolcapone. Prior data indicate cognitive effects of tolcapone are affected by this SNP. We hypothesize that the val/val COMT variant will be associated with significantly higher tolcapone-related improvements in cognition and symptoms, since this is linked to lower cortical dopamine function. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04934007 -
Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder
|
N/A | |
Recruiting |
NCT04071990 -
Family Involvement in CBGT of OCD: a Randomized Controlled Trial
|
N/A | |
Completed |
NCT02541968 -
Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Recruiting |
NCT05391503 -
Light Therapy for Obsessive-compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT04539951 -
Pragmatic Trial of Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT03416504 -
Methods for Managing Intrusive Thoughts
|
N/A | |
Not yet recruiting |
NCT06029738 -
Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD
|
N/A | |
Recruiting |
NCT02844049 -
European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS
|
N/A | |
Completed |
NCT02911324 -
Cannabinoid Medication for Adults With OCD
|
Phase 1/Phase 2 | |
Terminated |
NCT02909660 -
What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder
|
N/A | |
Terminated |
NCT02234011 -
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT02217995 -
Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients
|
N/A | |
Withdrawn |
NCT01953042 -
Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders
|
N/A | |
Completed |
NCT02655926 -
Deep Brain Stimulation for Severe Obsessive Compulsive Disorder
|
N/A | |
Completed |
NCT04919785 -
Deep Brain Stimulation in Severe Obsessive-compulsive Disorder
|
N/A | |
Terminated |
NCT00758966 -
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT00742664 -
Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project
|
Phase 1/Phase 2 | |
Completed |
NCT00523718 -
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT00074815 -
Treatment of Obsessive Compulsive Disorder in Children
|
Phase 3 |